Genmab A/S (NASDAQ:GMAB) Short Interest Up 32.5% in March

Genmab A/S (NASDAQ:GMAB - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 3,060,000 shares, a growth of 32.5% from the February 28th total of 2,310,000 shares. Based on an average daily volume of 1,460,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 0.5% of the company's stock are short sold.

Institutional Trading of Genmab A/S

Hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC raised its holdings in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its position in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares in the last quarter. Barclays PLC boosted its position in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC grew its holdings in Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on GMAB shares. Truist Financial cut their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of "Moderate Buy" and a consensus target price of $41.33.

Genmab A/S Price Performance

NASDAQ:GMAB traded up $0.35 during midday trading on Thursday, hitting $19.17. The company's stock had a trading volume of 626,005 shares, compared to its average volume of 969,261. The firm's 50 day moving average is $20.76 and its 200-day moving average is $21.71. Genmab A/S has a fifty-two week low of $18.48 and a fifty-two week high of $30.50. The firm has a market cap of $12.69 billion, a P/E ratio of 11.02, a P/E/G ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.